The IP focuses on the development of chimeric antigen receptor (CAR) targeting Nucleolin (NCL) expressing natural killer (NK) cells, offering a novel approach to cancer treatment. It has the ability to target NCL, a novel antigen in cancer immunotherapy that has not been previously utilized as a target for CAR-NK cells. By designing CARs targeting NCL and expressing them on the surface of NK cells, this technology demonstrates promising antitumor activity against various cancer types. The stage of development for this IP is currently conceptual, with proof-of-concept experiments demonstrating successful targeting of breast cancers. Further work is planned to verify the efficacy and specificity of CAR-NK cells against multiple other cancers through in vitro and in vivo assays. Its novelty in targeting NCL opens up new possibilities for cancer treatment, potentially expanding the repertoire of available therapies for patients. Additionally, the versatility of CAR-NK cells allows for targeting a wide range of cancers, including breast, lung, brain cancer, myeloid, and lymphoid leukemia, among others.